Optimization of a stability-indicating HPLC method for the simultaneous determination of rifampicin, isoniazid, and pyrazinamide in a fixed-dose combination using artificial neural networks

Journal of Chromatographic Science

Volumn 45, Issue 1, 2007, Pages 38-44

  Glass, B D ^a   Agatonovic Kustrin, S ^b   Chen, Y J ^c   Wisch, M H ^c  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c RHODES UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846240929     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/45.1.38     Document Type: Article

References (32)

1. A.M. Rouchi. Tuberculosis: A tough adversary. Chem. Ind News 77: 52-69 (1999).
2. World Health Organization TB Report 1998. World Health Organization Press Office, Geneva, Switzerland. 1998 pp. 1-198.
3. B. Blomberg, S. Spinaci, B. Fourie, and R. Laing. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bulletin of the World Health Organization. 79(1): 61-68 (2001).
4. The South African Medical Association. South African Medicines Formulary, 4th ed, C.J. Gibbon, Ed. UCT, Pioneer Press, Pretoria, South Africa, 1997, pp. 260-70.
5. G. Pelizza, M. Nebuloni, P. Ferrari, and G.G. Gallo. Polymorphism of rifampicin. Farmaco. 32: 471-81 (1977).
6. M.W. Long, D.E. Snider, Jr., and L.S. Farer. Public Health Service cooperative trial of three rifampicin-isoniazid regimens in treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. 119: 879-94 (1979).
7. World Health Organization, International Union Against Tuberculosis and Lung Desease. The promise and the reality of fixeddose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Program of the World Health Organization. Int. J. Tuberc. Lung Dis. 75: 180-81 (1994).
8. A.P. Argekar, S.S. Kunjir, and K.S. Purandare. Simultaneous determination of rifampicin, isoniazid and pyrazinamide by high performance thin layer chromatography. J. Pharm. Biomed. Anal. 14 (11): 1645-50 (1996).
9. E. Beretta, S. Botturi, P. Ferrari, G. Tuan, and L.F. Zerilli. Identification of 5-hydroxypyrazinamide isolated from urine of subjects given pyrazinamide. J. Chromatogr. 416(1): 144-49 (1987).
10. C.D. Gaitonde and P.V. Pathak. Rapid LC method for the estimation of isoniazid and pyrazinamide in plasma and urine. J. Chromatogr. 532 (2): 418-23 (1990).
11. C.D. Gaitonde and P.V. Pathak. Rapid and sensitive estimation of isoniazid, pyrazinamide and rifampicin in combined dosage form by reverse-phase liquid chromatography. Drug. Dev. Ind. Pharm. 17(9): 1201-14 (1991).
12. A. Defilippi, G. Piancone, R.C. Laia, S. Balla, and G.P. Tibaldi. HPLC with UV detection and diado-array UV conformation of isonicotinic acid hydrazide in cattle milk. J. Chromatogr. B Biomed. Appl. 656(2): 466-71 (1994).
13. M. Gidoh and S. Tsutsumi. Determination of three main anrileprosy drugs and their main metabolites in serum by HPLC. J. Chromatogr. 223(2): 371-92 (1981).
14. M. Guillaumont, M. Leclercq, Y. Frobert, and B. Guise. Determination of rifampicin, desacetylrifampicin, isoniazid and acetylisoniazid by HPLC: application to human serum extracts, polymorphonucleocytes and alveolar magrophages. J. Chromatogr. 232(2): 369-76 (1982).
15. P.J. Smith, J. van Dyk, and A. Fredericks. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma. Int. J. Tuberc. Lung. Dis. 3: 325-28 (1999).
16. K.C. Jindal, R.S. Chaudhary, A.K. Singla, S.S. Gangwal, and S. Khanna. Dissolution test method for rifampicin-isoniazid fixed dose formulations. J. Pharm. Biomed. Anal. 12(4): 493-97 (1994).
17. K.C. Jindal, R.S. Chaudhary, A.L. Singla, S.S. Gangwal, and S. Khanna. Effect of buffers and pH on rifampicin stability. Pharm. Ind. 57(5): 420-22 (1995).
18. S. Lachau, M.A. Rochas, A.E. Tufenkji, N. Martin, P. Levillain, and K. Houin. First-derivative spectroscopic deterimination of binding charateristic of rifampicin of human albumin and serum. J. Pharm. Sci. 81(3): 287-89 (1992).
19. G. Karlagains, E. Peretti, and B.H. Lauterburg. Analysis of isoniazid, acetylhydrazine and 15N2. acetylhydrazine in serum by capillary gas chromatography-ammonia chemical ionization mass spectrometry. J. Chromatogr. B Biomed. Appl. 420: 171-77 (1957).
20. B. Ratti, R.R. Parenti, A. Toselli, and L.F. Zerilli. Quantitative assay of rifampicin and its main metabolite 25-desacetykifampicin in human plasma by reverse phase HPLC. J. Chromatogr. B Biomed. Appl. 225(2): 526-31 (1981).
21. H.I. Seifart, W.L. Gent, D.P. Parkin, P.P. Van Jaarsveld, and P.R. Donald. High performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J. Chromatogr. B Biomed. Appl. 674: 269-75 (1995).
22. Y. Shah, S. Khanna, K.C. Jindal, and V.S. Dighe. Determination of rifampicin and isoniazid in pharmaceutical formulation by HPLC. Drug Dev. Ind. Pharm. 18(14): 1589-96 (1992).
23. V.P. Shah, K.K. Midha, S. Dighe, I.J. Mcgilveray, J.P. Skelly, A. Yacobi, T. Layloff, C.T. Viswanathan, C.E. Cook, R.D. Mcdowall, K.A. Pittman, and S. Spector. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetics studies. Europ . J. Drug. Metab. Pharmacokinet. 16(4): 249-55 (1991).
24. A. Walubo, K. Chan, and C.L. Wong. Simultaneous assay for isoniazid and hydrazine metabolite in plasma and cerebrospinal fluid in the rabbit. J Chromatogr. 567: 261-66 (1991).
25. J. Woo, C.L. Wang, I.L. Teoh, and K. Chan. LC assay for the simultaneous determination of pyrazinamide and rifampicin in serum samples from patients with tuberculous meningitis. J. Chromatogr. 420(1): 73-80 (1987).
26. T. Yamamoto, Y. Moriwaki, S. Takahashi, T. Hada, and K. Higashino. Rapid and simultaneous determination of pyrazinamide and its major metabolites in human plasma by HPLC. J. Chromatogr. 413: 342-6 (1987).
27. M. Egmont-Petersen, J.L. Talmo, and A. Hasman. Assessing the importance of features for multi-layer perceptrons. Neural Networks. 11: 623-35 (1998).
28. G. Bologna and C. Pellegrini. Three medical examples in neural network rule extraction. Phys. Medica 13: 183-87 (1997).
29. T.F. Rathbun, S.K. Rogers, and M.P. DeSimio. MLP iterative construction algorithm. Neurocomputing. 17: 195-216 (1997).
30. D.A. Skoog and J.J. Leary. Principles of Instrumental Analysis,4th ed. Saunders College Publishing, Philadelphia, PA, 1992.
31. D. Dadgar, P.E. Burnett, M.G. Choc, K. Gallicano, and J.W. Hooper. Application issues in bioanalytical method validation, sample analysis and data reporting. J. Pharm. Biomed. Anal. 13(2): 89-97 (1995).
32. J.C. Wahlich and G.P. Carr. Chromatographic system suitability test - what should we be using? J. Pharm. Biomed. Anal. 8(8-12): 619-23 (1990).